Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date January 03, 2019 · Filed January 16, 2019
Section 16 reporting ended · disclosed 2019-01-16. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2018 Filed Aug 9, 2018 20:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 55,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-18-010454 · edgar.xml · derivative · entry 3 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 55,000 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 5,136 | $39.30 | $201,844.80 |
DisclosureSEC source: 0001179110-18-010454 · edgar.xml · nonDerivative · entry 2 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,921 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 55000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 49,864 shares of common stock. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 55,000 | $3.67 | $201,850.00 |
DisclosureSEC source: 0001179110-18-010454 · edgar.xml · nonDerivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 55000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 49,864 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 18, 2018 22:25 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 10,000 | $43.47 | $434,700.00 |
DisclosureSEC source: 0001179110-18-007135 · edgar.xml · nonDerivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,057 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.95 to $43.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 12:55 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 3,260 | $27.40 | $89,324.00 |
DisclosureSEC source: 0001179110-18-002334 · edgar.xml · nonDerivative · entry 2 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,057 Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 12:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 7,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002334 · edgar.xml · nonDerivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,317 F1 · shares: Represents shares of common stock that have vested and settled in accordance with that certain PSU Agreement granted to the reporting person on December 29, 2016. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015740 · edgar.xml · derivative · entry 2 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 9,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015740 · edgar.xml · derivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 21:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,383 | $15.15 | $36,102.45 |
DisclosureSEC source: 0001179110-17-011153 · edgar.xml · nonDerivative · entry 2 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,167 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 21:10 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 7,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011153 · edgar.xml · nonDerivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,550 F1 · shares: Represents shares of common stock that have vested and settled in accordance with that certain PSU Agreement granted to the reporting person on December 29, 2016. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:44 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000080 · edgar.xml · derivative · entry 1 MCCARREY SHAWN F · CIK 0001195924 · SVP Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020(4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.